Case Report: Successful Treatment With Monoclonal Antibodies in One APDS Patient With Prolonged SARS-CoV-2 Infection Not Responsive to Previous Lines of Treatment

Case Report: Successful Treatment With Monoclonal Antibodies in One APDS Patient With Prolonged SARS-CoV-2 Infection Not Responsive to Previous Lines of Treatment

We described the case of a patient affected by activated PI3K-kinase delta syndrome (APDS) and a long-lasting and pauci-symptomatic SARS-CoV-2 infection, treated with multiple therapeutic agents including remdesivir and SARS-CoV-2-neutralizing monoclonal antibodies. We detected the clearance of the...

Full description

Bibliographic Details
Main Authors: Beatrice Rivalta, Donato Amodio, Carmela Giancotta, Veronica Santilli, Lucia Pacillo, Paola Zangari, Nicola Cotugno, Emma Concetta Manno, Andrea Finocchi, Stefania Bernardi, Luna Colagrossi, Leonarda Gentile, Cristina Russo, Carlo Federico Perno, Paolo Rossi, Caterina Cancrini, Paolo Palma
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Immunology
Subjects:
SARS-CoV-2
COVID19
IEI
activated PI3K delta syndrome (APDS)
monoclonal antibody
remdesivir
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.891274/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.891274/full

Similar Items